Biocartis Group 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Herman Verrelst

최고 경영자

€495.1k

총 보상

CEO 급여 비율	75.7%
CEO 임기	5.2yrs
CEO 소유권	n/a
경영진 평균 재임 기간	5.2yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Herman Verrelst 의 보수는 Biocartis Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2022	n/a	n/a	-€63m
Mar 31 2022	n/a	n/a	-€67m
Dec 31 2021	€495k	€375k	-€71m
Sep 30 2021	n/a	n/a	-€70m
Jun 30 2021	n/a	n/a	-€69m
Mar 31 2021	n/a	n/a	-€66m
Dec 31 2020	€502k	€375k	-€63m
Sep 30 2020	n/a	n/a	-€64m
Jun 30 2020	n/a	n/a	-€66m
Mar 31 2020	n/a	n/a	-€65m
Dec 31 2019	€448k	€375k	-€64m
Sep 30 2019	n/a	n/a	-€60m
Jun 30 2019	n/a	n/a	-€56m
Mar 31 2019	n/a	n/a	-€52m
Dec 31 2018	€510k	€375k	-€48m
Sep 30 2018	n/a	n/a	-€44m
Jun 30 2018	n/a	n/a	-€40m
Mar 31 2018	n/a	n/a	-€41m
Dec 31 2017	€232k	€137k	-€42m

보상 대 시장: Herman 의 총 보상 ($USD 492.25K )은 UK 시장( $USD 354.22K ).

보상과 수익: Herman 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Herman Verrelst (48 yo)

5.2yrs

테뉴어

€495,058

보상

Mr. Herman Verrelst serves as Director at FOx Diagnostics. He has been Chief Executive Officer of Biocartis Group NV since August 31, 2017. Mr. Verrelst served as the President of the Board at FOx Diagnost...

리더십 팀

이름	위치	테뉴어	보상	소유권
Herman Verrelst	CEO & Executive Director	5.2yrs	€495.06k	데이터 없음
Jean-Marc Roelandt	Chief Financial Officer	2.5yrs	데이터 없음	데이터 없음
Piet Houwen	Chief Operating Officer	3.5yrs	데이터 없음	데이터 없음
Benoit Devogelaere	Chief Technology Officer	4.8yrs	데이터 없음	데이터 없음
Geert Maertens	Chairman of Scientific Advisory Board & Chief Scientific Officer	no data	데이터 없음	데이터 없음
Renate Degrave	Head of IR & Corporate Communications	no data	데이터 없음	데이터 없음
Susy Spruyt	Head of People & Organization	7.8yrs	데이터 없음	데이터 없음
Erwin Sablon	Head of R&D and Alliance Management	10.2yrs	데이터 없음	데이터 없음
Reginald Van Genechten	Head of Manufacturing & Supply Chain	6.6yrs	데이터 없음	데이터 없음
Dirk Zimmermann	Global Head of Pharma Collaborations & Partnering	3.4yrs	데이터 없음	데이터 없음
Erik Vossenaar	Vice President of Business Development	6.8yrs	데이터 없음	데이터 없음

5.2yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: BCARTB 의 관리팀은 노련하고 경험 (평균 재직 기간 5.2 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Herman Verrelst	CEO & Executive Director	5.1yrs	€495.06k	데이터 없음
Geert Maertens	Chairman of Scientific Advisory Board & Chief Scientific Officer	no data	데이터 없음	데이터 없음
Christian Reinaudo	Independent Chairman of the Board	4.4yrs	€81.00k	데이터 없음
Jean-Louis Vincent	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ann-Christine Sundell	Non Executive Independent Director	4.8yrs	€43.50k	데이터 없음
Pasi Janne	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Alberto Bardelli	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Eric Cutsem	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Roald Borré	Non-Executive Director	8.8yrs	€38.50k	데이터 없음
Josep Tabernero	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Luc Gijsens	Non-Executive Independent Director	4.8yrs	€46.00k	데이터 없음
Michael Press	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: BCARTB 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

Biocartis Group 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Insufficient new directors

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Insufficient new directors

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Insufficient new directors

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령